Stockscreener 앱 받기
0.70
1.41%
-0.01
시간 외 거래:
.70
Promis Neurosciences Inc 주식(PMN)의 최신 뉴스
ProMIS Neurosciences stock hits 52-week low at $0.62 - Investing.com India
ProMIS Neurosciences stock hits 52-week low at $0.62 By Investing.com - Investing.com South Africa
ProMIS Neurosciences’ (PMN) “Buy” Rating Reiterated at Guggenheim - Defense World
ProMIS Neurosciences begins Alzheimer's trial dosing - Investing.com India
ProMIS Neurosciences Advances Phase 1b Alzheimer’s Trial - TipRanks
GT Biopharma Announces Request for Withdrawal of Form S-1 Registration Statement - The Manila Times
ProMIS Neurosciences begins Alzheimer’s trial dosing - Investing.com
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer’s Disease - GlobeNewswire
ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for ... - The Bakersfield Californian
Multiple System Atrophy Clinical Trials and Pipeline 2025: EMA, - openPR
ProMIS Neurosciences Announces COO Position Termination - TipRanks
ProMIS Neurosciences stock hits 52-week low at $0.85 By Investing.com - Investing.com Nigeria
ProMIS Neurosciences dismisses COO position - MSN
ProMIS Neurosciences announces COO departure - Investing.com
ProMIS Neurosciences stock hits 52-week low at $0.85 - Investing.com
Promis Neurosciences chief scientific officer buys $14,595 in shares - MSN
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.
Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel - GlobeNewswire
StockNews.com Initiates Coverage on Beasley Broadcast Group (NASDAQ:BBGI) - Defense World
Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference - The Manila Times
ProMIS Neurosciences to Participate in Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Inside ProMIS's Game-Changing Approach to Neurodegenerative Diseases: CEO Reveals Latest Developments - StockTitan
ProMIS Neurosciences Updates Corporate Presentation in Recent 8-K Filing - Defense World
Vanda Pharmaceuticals Files for New Drug Application for Tradipitant for Motion Sickness Treatment - Defense World
ProMIS Neurosciences Highlights Neurodegenerative Disease Focus - TipRanks
ProMIS Neurosciences launch Phase Ia AβO Alzheimer’s trial - MSN
LANTRONIX Appoints Brent Stringham as Chief Financial OfficerIRVINE, Calif. – Lantronix, Inc. (NASDAQ: LTRX), a prominent provider of IoT compute and connectivity solutions, has announced the appointment of Brent Stringham as its new Chief Financial - ETF Daily News
ProMIS Neurosciences Issues Letter to Shareholders - Markets Insider
Crude Oil WTI (CLN25) Quote - The Globe and Mail
Crude Oil Brent (F) (QAJ23) Quote - The Globe and Mail
ProMIS Neurosciences Launches Phase 1b Trial for Alzheimer’s - TipRanks
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease - The Manila Times
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones - The Manila Times
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease - GlobeNewswire
ProMIS Neurosciences faces Nasdaq delisting over share price - Investing.com
Nonfat Dry Milk (DFZ25) Quote - The Globe and Mail
Berkshire Hathaway Cl B (BRK-B-N) QuotePress Release - The Globe and Mail
ProMIS Neurosciences (NASDAQ:PMN) Shares Up 2.8% – Should You Buy? - Defense World
ProMIS Neurosciences stock hits 52-week low at $0.88 By Investing.com - Investing.com Nigeria
ProMIS Neurosciences stock hits 52-week low at $0.88 - Investing.com
Vertiv Holdings Llc. (VRT-N) QuotePress Release - The Globe and Mail
ProMIS Neurosciences, Inc. (NASDAQ:PMN) Short Interest Down 16.6% in November - Defense World
ProMIS Neurosciences to Participate in 7th Annual Evercore HealthCONx Conference - GlobeNewswire
ProMIS Neurosciences stock hits 52-week low at $0.91 - Investing.com
ProMIS Neurosciences stock hits 52-week low at $0.91 By Investing.com - Investing.com Australia
13th Alzheimers and Parkinsons Drug Development Summit - PharmiWeb.com
ProMIS Neurosciences Announces Third Quarter Financial Results and Recent HighlightsOn November 14, 2024, ProMIS Neurosciences Inc. (Nasdaq: PMN) shared its financial outcomes for the third quarter ended September 30, 2024. The company provide - Defense World
ProMIS Neurosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
3.13%
1.23%
자본화:
|
볼륨(24시간):